Evidence map›Paper›PMID 42675099›Full record

ArticleScientific reports2026

Development of new imidazopyridine-based chalcones hybrids as potent antidiabetic and antioxidant agents: synthesis, in silico and in vitro evaluation.

Hanan Abdelmawgoud Atia, Aladdin M Srour, Hanaa Farag, Wael Mahmoud Aboulthana, Abdulrahman M Saleh, Mohamed Gamal Thabit, Ranza Elrayess, Asmaa Saleh, Jarosław Dziadek, Ahmed Sabt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanan Abdelmawgoud AtiaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, 55473, Saudi Arabia.
Aladdin M SrourDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Giza, 12622, Egypt.
Hanaa FaragPesticide Chemistry Department, Chemical Industries Research Institute, National Research Centre, Cairo, 12622, Egypt.
Wael Mahmoud AboulthanaBiochemistry Department, Biotechnology Research Institute, National Research Centre, 33 El Bohouth St, P.O. 12622, Dokki, Giza, Egypt.
Abdulrahman M SalehPostgraduate program in Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt.
Mohamed Gamal ThabitDepartment of Pharmaceutical Chemistry, Pharos University in Alexandria, Canal El Mahmoudia Street, Beside Green Plaza complex 21648, Alexandria, Egypt.
Ranza ElrayessPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Asmaa SalehDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Jarosław DziadekLaboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland. jdziadek@cbm.pan.pl.
Ahmed SabtChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, 12622, Cairo, Egypt. sabt.nrc@gmail.com.

Funding

Ministry of Science and Higher Education, POLOPENSCREEN, 2024/WK/06.the Princess Nourah bint Abdulrahman University Researchers Supporting PNURSP2026R141
6 · The paper itself

Abstract

Nowadays, diabetes mellitus (DM) is a rapidly growing global health concern. In this study, we synthesized a novel series of six imidazopyridine-based chalcone hybrids (5a-f) and evaluated their in vitro biological activities, including total antioxidant capacity, iron-reducing power, and radical scavenging (DPPH, ABTS, NO), as well as antidiabetic potential against α-amylase, α-glucosidase, and aldose reductase. All compounds showed moderate to potent activity, with derivatives 5c and 5f being the most effective. Compound 5f exhibited the highest antioxidant performance (total capacity: 78.63 mg GAE/g; reducing power: 68.88 µg/ml) and strong radical scavenging (IC

Indexed as

AntioxidantsChalconesHypoglycemic AgentsImidazolesPyridinesAldehyde Reductasealpha-Amylasesalpha-GlucosidasesMolecular Docking SimulationStructure-Activity RelationshipAldehyde Reductasealpha-Amylasesalpha-GlucosidasesAntioxidantsChalconesHypoglycemic AgentsImidazolesimidazopyridinePyridinesAntidiabetic & Antioxidant activityImidazopyridinMolecular dynamics simulationsSynthesis

Identifiers

PMID42675099
PMCPMC13529672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.